Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 Dear fellow shareholder, It is my pleasure to present the Genetic Signatures annual report for the year ended 30 June 2021. Genetic Signatures has had another excellent year that delivered a dramatic increase in revenue and our first profitable full year in the company’s history. Excellent progress was made on a number of fronts across the product portfolio of molecular pathogen testing, over and above tests for the SARS-CoV-2 virus that causes COVID-19. The COVID-19 pandemic remains an ongoing backdrop for the company and for the community in general. Amid renewed and challenging lockdowns, management has been able to ensure the continued supply of testing kits to our customers while keeping staff safe. All staff are proud of the role that Genetic Signatures has played in providing the diagnostic tools to help limit the spread of COVID-19. I personally would like to commend each member of the Genetic Signatures global team for their dedication in performing their unique role in ensuring the Company’s critically important tests have contributed to the safety of the community in the ongoing period of the COVID-19 pandemic. Hopefully, increasing vaccination rates will help supress COVID-19. But with elimination of the SARS- CoV-2 virus increasingly difficult to achieve in the short term, citizens globally are likely going to have to coexist with the disease in one way or the other and this would imply strong ongoing demand for regular streamlined testing. To date, more than three million Genetic Signatures diagnostic tests of all types have been undertaken on patient samples. Based on our proprietary 3base ™ technology and sold under the EasyScreen ™ brand, these tests can detect groups of organisms – up to 20 at a time – from the one patient sample. While SARS-CoV-2 has been a contributor to the growth in revenue and overall financial performance, Genetic Signatures continues to focus on the development of its broader testing capabilities. Work continues on several new products that are at different stages of development, to supplement those products that have already received regulatory registrations in various global jurisdictions. This investment in R&D programs is targeting multiple new revenue opportunities. For example, European authorities registered the EasyScreen ™ STI/Genital Pathogen Detection Kit during the year, which now brings to five Chairman’s Letter